Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment

Authors

Irene Litvan, Department of Neurosciences
Karl Kieburtz, University of Rochester Medical Center
Alexander I. Tröster, Barrow Neurological Institute
Dag Aarsland, King's College London

Document Type

Article

Abstract

Treatments to slow the progression of cognitive dysfunction to dementia and improve the quality of life of persons with Parkinson's disease (PD) are desperately needed. Because PD mild cognitive impairment is considered a transitional stage before dementia, it opens a window to timely intervention. This article critically reviews the strengths and challenges of pharmacologic and nonpharmacologic clinical therapeutic trials in PD mild cognitive impairment conducted during the past 5 years, including ongoing trials. Relatively few high-quality trials have been conducted, and some important factors in designing future clinical trials are discussed. © 2018 International Parkinson and Movement Disorder Society.

Publication Date

4-1-2018

Publication Title

Movement Disorders

ISSN

08853185

E-ISSN

15318257

Volume

33

Issue

4

First Page

520

Last Page

527

PubMed ID

29573469

Digital Object Identifier (DOI)

10.1002/mds.27345

Recommended Citation

Litvan, Irene; Kieburtz, Karl; Tröster, Alexander I.; and Aarsland, Dag, "Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment" (2018). Clinical Neuropsychology. 125.
https://scholar.barrowneuro.org/neuropsychology/125